The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study

Table 2

Description of occult malignancy cases ().

	Case number 1	Case number 2	Case number 3	Case number 4
Age (on the day of prophylactic mastectomy)	34 years	41 years	40 years	32 years
Genetic risk	BRCA1	BRCA1	BRCA2	BRCA1
Surgery indication	Prophylactic + therapeutic	Prophylactic +; therapeutic	Bilateral prophylactic	Contralateral prophylactic
Breast cancer characteristics; (therapeutic side or breast cancer in the past)	(i) Invasive, not otherwise specified, histologic grade 2; (ii) Estrogen receptor 100%. Progesterone receptor 10%; Cerb2 negative; (iii) cT1N0; (iv) pT1cN0(sn)	(i) Invasive, not otherwise specified carcinoma, histologic grade 2; (ii) Triple negative; (iii) cT1N0; (iv) pT2N0(sn)	-	2 years before prophylactic mastectomy(i) Invasive not otherwise specified carcinoma, histologic grade 3; (ii) Triple negative; (iii) cT3N1; (iv) Neoadjuvant chemotherapy. Radical mastectomy. Radiotherapy (unknown pathological response to chemotherapy)
Mammography/ultrasound	No findings	No findings	Dense pattern	Stable asymmetry
MRI (prophylactic side)	BI-RADS 2	BI-RADS 2	BI-RADS 2 (bilaterally)	Contraindication for MRI
Time interval from MRI to prophylactic mastectomy	103 days	84 days	97 days	-
Occult carcinoma histological; findings	Ductal carcinoma in situ (6 mm)	Ductal carcinoma in situ (10 mm)	Lobular microinvasive and lobular in situ multifocal; Estrogen receptor in in situ component-positive	Invasive, not otherwise specified (2 mm); Estrogen and progesterone receptor-negative
Sentinel lymph node biopsy	Not done	Not done	Not done	Not done
Follow-up	(i) 24 months; (ii) No local or distant recurrence	(i) 63 months; (ii) No local or distant recurrence	(i) 30 months; (ii) No local or distant recurrence	(i) 29 months; (ii) No local or distant recurrence

BI-RADS: Breast Imaging-Reporting and Data System Classification.